Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 18/20 | 0.68 |
| ▸ | HSP90AB1 | P08238 | 9/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2079367 | 0.92 | HSP90AA1 (0.69) | HSP90AA1HSP90AB1NPC1 | |
| SCHEMBL2079305 | 0.90 | HSP90AA1 (0.67) | HSP90AA1HSP90AB1NPC1 | |
| SCHEMBL1218650 | 0.90 | HSP90AA1 (0.66) | HSP90AA1HSP90AB1NPC1 | |
| SCHEMBL2079168 | 0.89 | HSP90AA1 (0.65) | HSP90AA1HSP90AB1 | |
| SCHEMBL2080012 | 0.89 | HSP90AA1 (0.65) | HSP90AA1HSP90AB1NPC1 | |
| SCHEMBL2081204 | 0.89 | HSP90AA1 (0.65) | HSP90AA1HSP90AB1ALDH1A1 | |
| SCHEMBL2080013 | 0.89 | HSP90AA1 (0.65) | HSP90AA1HSP90AB1NPC1 | |
| SCHEMBL2080017 | 0.89 | HSP90AA1 (0.67) | HSP90AA1HSP90AB1MAPT | |
| SCHEMBL2079264 | 0.88 | HSP90AA1 (0.76) | HSP90AA1HSP90AB1 | |
| SCHEMBL2077784 | 0.87 | HSP90AA1 (0.67) | HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2018370-B1 | 1,5-DIPHENYLPYRAZOLES II AS HSP90 INHIBITORS | MERCK PATENT GMBH (DE) | 2013-03-27 | — | — | EP | claimed |
| US-7906657-B2 | 1,5-diphenylpyrazoles II as HSP90 inhibitors | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2011-03-15 | — | — | US | claimed |
| US-20090325974-A1 | 1,5-DIPHENYLPYRAZOLES II AS HSP90 INHIBITORS | MERCK PATENT GESELLSCHAFT (DE) | 2009-12-31 | — | — | US | claimed |
| EP-2018370-B1 | 1,5-DIPHENYLPYRAZOLES II AS HSP90 INHIBITORS | MERCK PATENT GMBH (DE) | 2013-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325974-A1 | 1,5-DIPHENYLPYRAZOLES II AS HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AA1 2/4885HSP90AB1 1/4885NPC1 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.